Methods	Six-week randomised, double-blind study.
Participants	Outpatients fulfilling DSM-III-R criteria for major depressive disorder or dysthymic disorder or depressive disorder NOS and Columbia criteria for atypical depression, with a score of at least 10 on the HDRS-17. Mean age: 32.8 (fluoxetine) and 34.3 (phenelzine) years old. Exclusion criteria: pregnancy, serious medical illness, comorbid psychiatric illness, alcohol or drug abuse, partecipation to a clinical trial in the previous month
Interventions	Fluoxetine: 20 participants. Phenelzine: 20 participants. Fluoxetine dose range: 20-60 mg/day. Phenelzine dose range: 45-90 mg/day.
Outcomes	Hamilton Rating Scale for Depression (HDRS-17), CGI-S, CGI-I, PGI
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear